Where does Innate Pharma rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Innate Pharma ranks #4,721 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Innate Pharma hold?

Innate Pharma holds 74 US utility patents granted between 2015 and 2025, spanning 12 technology areas.

What is Innate Pharma's Innovation Score?

Innate Pharma has an Innovation Score of 41.5 out of 100 (top 33% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Innate Pharma focus on?

Innate Pharma's top technology area is C07K (Peptides) with 74 patents, ranking #111 of 3,615 assignees active in that subclass. Grants appear in 12 CPC subclasses total.

Is Innate Pharma's patent grant rate increasing or decreasing?

Innate Pharma's recent grant velocity is +9% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Innate Pharma's patents?

Innate Pharma's patents average 15.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Innate Pharma patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Innate Pharma

USPTO PatentsView assignee record - 74 granted patents across 12 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Innate ranks #4,721 of 49,997 tracked US assignees by granted-patent volume, with 74 patents across 12 technology areas.

#4,721
of 49,997 US assignees by volume: Top 33%
by Innovation Score (41.5/100): 15.8
avg claims per patent: +9%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4721 · Foreign Corporation #4,721 · 74 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL

GRANTS-SMALL 74 grants
TOP-DECILE #4,721/49,997
PHOTO-FINISH Health Research
CPC-FOCUS C07K · 12 areas
INNOV-PAR 41.5/100
CLAIMS-RICH 15.8 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-FLAT +9% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Health Research, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Innate’s 41.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 14.9 pts (36%) Velocity 4.9 pts (12%) Breadth 12.2 pts (29%) Claim depth 9.5 pts (23%)

Qualcomm Incorporated · highest

85
Innate Pharma · this assignee

42
Interaptix · near

42
Lensvector · near

42
Nissin Foods Holdings · near

42
Technology Research… · near

42
3D Lighting… · lowest

7

What this shows Innate's Innovation Score is 41.5/100 (top 33% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Innate?

Each dot is one of Innate’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Innate’s own 15.8 claims/patent is ABOVE the 12.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Innate vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Innate's grants concentrate

Innate Pharma is a focused PatentsView assignee: 12 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2020 (10 grants) versus a trough of 4 in 2016. By volume, Innate sits between Health Research, Inc. and Keystone Retaining Wall Systems, LLC.

Innate's three-year grant acceleration

From 2019–2021 to 2022–2024, Innate Pharma moved from 26 to 19 grants (0.73x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Health Research

74
Hefei Hualing

74
Huntsman Petroche…

74
Imflux

74
Irwin Industrial…

74
Johnson Matthey

74
Kaohsiung Medical…

74
Keystone Retainin…

74
Innate Pharma ◀

74

What this shows Innate holds 74 patents at rank #4,721, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Innate

By rank, the assignees closest to #4,721 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Innate's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Innate, neither rank-band nor same-CPC leaders (those blocks stay above). In C07K (Peptides), Innate ranks #111 of 3,615 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (42 here).

Technology Research Association FOR Future Additive Manufacturing 42 Nissin Foods Holdings Co., Ltd. 42 Lensvector 42 Interaptix Inc. 42

Similar claim depth

Nearest assignees by average claims per patent (15.8 here).

The Schepens Eye Research Institute, Inc. 15.8 avg Samsung Medison Co., Ltd. 15.8 avg MOR Research Applications Ltd. 15.8 avg Hytto PTE. Ltd. 15.8 avg

Innate's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 33% higher than 67% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Innate Pharma patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	6	8.1%
2016	4	5.4%
2017	6	8.1%
2018	8	10.8%
2019	9	12.2%
2020	10	13.5%
2021	7	9.5%
2022	6	8.1%
2023	6	8.1%
2024	7	9.5%
2025partial year	5	6.8%

Which technologies does Innate Pharma patent most?

C07K - Peptides 74

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 69

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 59

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 26

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 11

Y02A - Technologies FOR Adaptation TO Climate Change 4

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 4

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 3

C07D - Heterocyclic Compounds 3

C07C - Acyclic OR Carbocyclic Compounds 3

C40B - Combinatorial CHEMISTRY; Libraries, e.g. Chemical Libraries 1

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 1

Top 12 of 12 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Innate Pharma's patent record in context - here's where to go next.

Innate Pharma's lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #4,721 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Innate Pharma against Health Research, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 41.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.